16 completed. 16 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 16 | Completed 16 |
Follow Levodopa: new trials by email Literature Review of Levodopa trials Research Report on Levodopa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs. Opicapone, L-DOPA/DDCI - Parkinson Disease | Phase 4 | Completed | Bial - Portela C S.A. | 106 | 2021-11-29 | 2025-03-12 |
| DTA (Dopaminergic Therapy for Anhedonia) Study Carbidopa Levodopa, Placebo - Depression, Anhedonia | Phase 4 | Completed | Emory University | 19 | 2021-01-29 | 2024-12-16 |
| Vigor and the LDR in Parkinson Disease carbidopa/levodopa, as prescribed by treating physician - Parkinson Disease | Phase 4 | Completed | University of Michigan | 19 | 2020-02-12 | 2025-07-18 |
| A Study of L-DOPA for Depression and Slowing in Older Adults Levodopa - Major Depressive Disorder, Dysthymia | Phase 4 | Completed | New York State Psychiatric Institute | 47 | 2016-08-24 | 2023-06-13 |
| Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753) Placebo, Levodopa - Stress Disorder, Post Traumatic | Phase 4 | Completed | University of Wisconsin, Madison | 103 | 2016-03-01 | 2019-06-25 |
| Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ON Levodopa dispersible, Levodopa - Parkinson Disease | Phase 4 | Completed | Seoul National University Hospital | 40 | 2015-06-01 | 2021-05-07 |
| Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) APOKYN, L-dopa, Trimethobenzamide - Parkinson's Disease, Motor Symptoms | Phase 4 | Completed | MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals | 127 | 2012-12-01 | 2023-08-14 |
| Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa Levodopa/Carbidopa(200mg/50mg), Dopaminergic Agonists - Impulse Control Disorder | Phase 4 | Completed | Sandoz | 150 | 2012-11-01 | 2021-03-10 |
| Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off Levodopa/carbidopa/entacapone, Levodopa/carbidopa - Parkinson's Disease | Phase 4 | Completed | Novartis | 95 | 2006-10-01 | 2011-03-15 |
| A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease rasagiline mesylate, Rasagiline mesylate plus Mirapex, Rasagiline mesylate with Levodopa - Parkinson's Disease | Phase 4 | Completed | Teva Neuroscience, Inc. | 200 | 2006-10-01 | 2011-04-12 |
| Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit Levodopa (drug), intraduodenal administration - Parkinson Disease | Phase 4 | Completed | University Hospital, Akershus | 10 | 2006-01-01 | 2015-12-30 |
| Stalevo in Early Wearing-Off Patients Stalevo (levodopa/carbidopa/entacapone), Levodopa/carbidopa - Idiopathic Parkinson's Disease | Phase 4 | Completed | Orion Corporation, Orion Pharma | 223 | 2005-08-01 | 2009-06-22 |
| Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's Disease Cabergoline, Levodopa - Parkinson's Disease | Phase 4 | Completed | Technische Universität Dresden | 39 | 2005-02-01 | 2012-12-18 |
| Dopaminergic Enhancement of Learning and Memory in Aphasia levodopa - Cerebrovascular Accident, Aphasia | Phase 4 | Completed | University Hospital Muenster | 12 | 2005-01-01 | 2013-10-07 |
| Improved Language Acquisition With Levodopa levodopa - Healthy | Phase 4 | Completed | University Hospital Muenster | 20 | 2003-03-01 | 2014-05-21 |
| Effect of Levodopa on Human Multifocal Electroretinogram levodopa - Retinal Diseases | Phase 4 | Completed | Medical University of Vienna | 20 | 2001-10-01 | 2008-12-22 |
Parkinson Disease (9) · Anhedonia (1) · Aphasia (1) · Depression (1) · Depressive Disorder, Major (1) · Disruptive, Impulse Control, and Conduct Disorders (1) · Dysthymic Disorder (1) · Retinal Diseases (1) · Stress Disorders, Post-Traumatic (1) · Stroke (1)
University Hospital Muenster (2) · Bial - Portela C S.A. (1) · Emory University (1) · MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals (1) · Medical University of Vienna (1) · New York State Psychiatric Institute (1) · Novartis (1) · Orion Corporation, Orion Pharma (1) · Sandoz (1) · Seoul National University Hospital (1) · Technische Universität Dresden (1) · Teva Neuroscience, Inc. (1) · University Hospital, Akershus (1) · University of Michigan (1) · University of Wisconsin, Madison (1)
Germany (5) · United States (5) · South Korea (2) · Spain (2) · United Kingdom (2) · Austria (1) · Denmark (1) · Finland (1) · Ireland (1) · Italy (1) · Norway (1) · Portugal (1) · Sweden (1)
Caterina Breitenstein, PhD (2) · Stefan Knecht, MD (2) · Andrew Wighton, BSc (Hons) (1) · Antonie Beiske, PhD, M.D. (1) · Bhadravati SD Sastry, FRCP (1) · Bret Rutherford, MD (1) · Christofer Lundqvist, PhD, M.D. (1) · Gianpiera H. Ceresoli-Borroni, PhD (1) · Heinz Reichmann, MD (1) · Jee-Young Lee, MD, PhD (1) · Jennifer Felger, PhD (1) · Jinwhan Cho, MD (1) · Josh Cisler, PhD. (1) · MerriKay Oleen-Burkey, PhD (1)
PMID 21553090, PMID 25588456, PMID 30361296, PMID 31178096, PMID 32919398, PMID 34260994
R21NS114749 (1), R61MH121625 (1)